Genomic Health Company Profile (NASDAQ:GHDX)

About Genomic Health (NASDAQ:GHDX)

Genomic Health logoGenomic Health, Inc. is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company's Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test. Its research and development activities are focused on developing a pipeline of tests to optimize the treatment of various cancers including breast, colon, prostate and other cancers. It offers its Oncotype DX tests as a clinical laboratory service, where it analyzes the expression levels of genes in tumor tissue samples and provides physicians with a quantitative gene expression profile expressed as a single quantitative score, which it calls a Recurrence Score for invasive breast cancer and colon cancer, a DCIS Score for ductal carcinoma in situ (DCIS), and a Genomic Prostate Score, for prostate cancer.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research - NEC
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:GHDX
  • CUSIP: 37244C10
  • Web: www.genomichealth.com
Capitalization:
  • Market Cap: $1.13 billion
  • Outstanding Shares: 34,342,000
Average Prices:
  • 50 Day Moving Avg: $32.65
  • 200 Day Moving Avg: $30.91
  • 52 Week Range: $25.66 - $33.97
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 103.13
  • P/E Growth: 300.36
Sales & Book Value:
  • Annual Revenue: $330.95 million
  • Price / Sales: 3.42
  • Book Value: $4.69 per share
  • Price / Book: 7.04
Profitability:
  • EBIDTA: ($188,999.00)
  • Net Margins: -2.53%
  • Return on Equity: -6.80%
  • Return on Assets: -5.26%
Debt:
  • Current Ratio: 3.87%
  • Quick Ratio: 3.87%
Misc:
  • Average Volume: 115,878 shs.
  • Beta: 0.78
  • Short Ratio: 6.62
 
Frequently Asked Questions for Genomic Health (NASDAQ:GHDX)

What is Genomic Health's stock symbol?

Genomic Health trades on the NASDAQ under the ticker symbol "GHDX."

How were Genomic Health's earnings last quarter?

Genomic Health, Inc. (NASDAQ:GHDX) issued its quarterly earnings data on Tuesday, May, 9th. The company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of ($0.06) by $0.01. The business earned $84 million during the quarter, compared to analysts' expectations of $86.21 million. Genomic Health had a negative return on equity of 6.80% and a negative net margin of 2.53%. The company's revenue was up 3.8% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.19) earnings per share. View Genomic Health's Earnings History.

Where is Genomic Health's stock going? Where will Genomic Health's stock price be in 2017?

7 brokerages have issued twelve-month price targets for Genomic Health's stock. Their predictions range from $27.00 to $38.00. On average, they anticipate Genomic Health's stock price to reach $31.83 in the next year. View Analyst Ratings for Genomic Health.

Who are some of Genomic Health's key competitors?

Who are Genomic Health's key executives?

Genomic Health's management team includes the folowing people:

  • Kimberly J. Popovits, Chairman of the Board, President, Chief Executive Officer
  • Gordon Bradley Cole, Chief Financial Officer, Chief Operating Officer, Secretary
  • Steven Shak M.D., Chief Scientific Officer
  • Julian C. Baker, Lead Independent Director
  • Geoffrey M. Parker, Director
  • Felix J. Baker Ph.D., Independent Director
  • Fred E. Cohen Ph.D., M.D., Independent Director
  • Henry J. Fuchs M.D.,Ph.D., Independent Director

Who owns Genomic Health stock?

Genomic Health's stock is owned by a variety of of retail and institutional investors. Top institutional investors include BAKER BROS. ADVISORS LP (40.90%), Tributary Capital Management LLC (0.96%), Bank of Montreal Can (0.13%), First National Bank of Omaha (0.07%), Acadian Asset Management LLC (0.07%) and Strs Ohio (0.07%). Company insiders that own Genomic Health stock include Felix Baker, Fred E Cohen, G Bradley Cole, James J Vaughn, Kimberly J Popovits, Laura Leber, Phillip G Febbo, Randall S Livingston and Steven Shak. View Institutional Ownership Trends for Genomic Health.

Who sold Genomic Health stock? Who is selling Genomic Health stock?

Genomic Health's stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Russell Investments Group Ltd., Independent Portfolio Consultants Inc., Strs Ohio, Boston Advisors LLC and First National Bank of Omaha. Company insiders that have sold Genomic Health stock in the last year include Fred E Cohen, G Bradley Cole, James J Vaughn, Kimberly J Popovits, Laura Leber, Phillip G Febbo and Steven Shak. View Insider Buying and Selling for Genomic Health.

Who bought Genomic Health stock? Who is buying Genomic Health stock?

Genomic Health's stock was acquired by a variety of institutional investors in the last quarter, including Tributary Capital Management LLC, Acadian Asset Management LLC and Dubuque Bank & Trust Co.. View Insider Buying and Selling for Genomic Health.

How do I buy Genomic Health stock?

Shares of Genomic Health can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Genomic Health's stock price today?

One share of Genomic Health stock can currently be purchased for approximately $33.00.


MarketBeat Community Rating for Genomic Health (NASDAQ GHDX)
Community Ranking:  1.7 out of 5 ()
Outperform Votes:  119 (Vote Outperform)
Underperform Votes:  225 (Vote Underperform)
Total Votes:  344
MarketBeat's community ratings are surveys of what our community members think about Genomic Health and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Genomic Health (NASDAQ:GHDX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Sell Ratings, 4 Hold Ratings, 1 Buy Rating
Consensus Rating:Hold (Score: 1.86)
Consensus Price Target: $31.83 (3.54% downside)

Analysts' Ratings History for Genomic Health (NASDAQ:GHDX)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
6/12/2017Jefferies Group LLCReiterated RatingHold$33.00LowView Rating Details
5/3/2017Raymond James Financial, Inc.Reiterated RatingOutperform -> Market PerformHighView Rating Details
1/23/2017Canaccord GenuitySet Price TargetBuy$38.00N/AView Rating Details
1/18/2017Deutsche Bank AGReiterated RatingHold$31.00N/AView Rating Details
1/9/2017Barclays PLCReiterated RatingSell$27.00N/AView Rating Details
1/4/2017Cowen and CompanyDowngradeOutperform -> Market Perform$35.00 -> $34.00N/AView Rating Details
8/3/2016Bank of America CorporationSet Price TargetSell$28.00N/AView Rating Details
6/21/2016Leerink SwannReiterated RatingBuyN/AView Rating Details
2/11/2016Piper Jaffray CompaniesReiterated RatingIn-Line$32.00 -> $31.00N/AView Rating Details
11/2/2015JMP SecuritiesBoost Price TargetOutperform$34.00 -> $36.00N/AView Rating Details
(Data available from 7/26/2015 forward)

Earnings

Earnings History for Genomic Health (NASDAQ:GHDX)
Earnings by Quarter for Genomic Health (NASDAQ:GHDX)
Earnings History by Quarter for Genomic Health (NASDAQ GHDX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2017Q1 2017($0.06)($0.07)$86.21 million$84.00 millionViewListenView Earnings Details
2/14/2017Q416($0.01)$0.04$84.08 million$82.70 millionViewListenView Earnings Details
11/1/2016Q316($0.09)($0.08)$83.24 million$82.30 millionViewN/AView Earnings Details
8/2/2016Q216($0.18)($0.18)$81.27 million$81.97 millionViewN/AView Earnings Details
5/4/2016Q1($0.24)($0.19)$78.12 million$80.89 millionViewN/AView Earnings Details
2/10/2016Q415($0.09)($0.10)$74.03 million$74.50 millionViewListenView Earnings Details
11/3/2015Q315($0.18)($0.36)$73.35 million$73.60 millionViewN/AView Earnings Details
8/4/2015Q215($0.27)($0.29)$71.65 million$70.60 millionViewListenView Earnings Details
5/5/2015Q115($0.28)($0.30)$69.30 million$68.15 millionViewN/AView Earnings Details
2/10/2015Q414($0.21)($0.20)$72.20 million$69.10 millionViewN/AView Earnings Details
11/4/2014Q314($0.22)($0.20)$71.00 million$69.10 millionViewN/AView Earnings Details
8/7/2014Q214($0.28)($0.15)$69.04 million$70.50 millionViewN/AView Earnings Details
5/6/2014Q114($0.18)($0.24)$68.47 million$67.00 millionViewN/AView Earnings Details
2/4/2014Q413($0.03)($0.30)$69.20 million$68.80 millionViewN/AView Earnings Details
11/5/2013Q313($0.04)$0.02$64.98 million$65.99 millionViewN/AView Earnings Details
7/31/2013Q2 2013($0.08)($0.10)$63.91 million$63.70 millionViewN/AView Earnings Details
5/2/2013Q1 2013($0.02)($0.03)$62.90 million$63.10 millionViewN/AView Earnings Details
2/6/2013Q4 2012$0.03$0.06$58.90 million$60.40 millionViewN/AView Earnings Details
11/7/2012Q312$0.05$0.11$59.87 million$58.60 millionViewN/AView Earnings Details
8/8/2012($0.02)$0.06ViewN/AView Earnings Details
5/2/2012($0.02)$0.02ViewN/AView Earnings Details
2/6/2012$0.09$0.08ViewN/AView Earnings Details
11/1/2011$0.03$0.10ViewN/AView Earnings Details
8/3/2011$0.02$0.08ViewN/AView Earnings Details
5/3/2011$0.02($0.01)ViewN/AView Earnings Details
2/8/2011$0.06$0.06ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Genomic Health (NASDAQ:GHDX)
2017 EPS Consensus Estimate: $0.01
2018 EPS Consensus Estimate: $0.22
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.08)$0.02($0.03)
Q2 20172($0.07)($0.07)($0.07)
Q3 20172$0.01$0.02$0.02
Q4 20172$0.08$0.11$0.10
Q1 20181$0.05$0.05$0.05
Q2 20181$0.05$0.05$0.05
Q3 20181$0.06$0.06$0.06
Q4 20181$0.06$0.06$0.06
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Genomic Health (NASDAQ:GHDX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Genomic Health (NASDAQ:GHDX)
Insider Ownership Percentage: 46.20%
Institutional Ownership Percentage: 89.45%
Insider Trades by Quarter for Genomic Health (NASDAQ:GHDX)
Institutional Ownership by Quarter for Genomic Health (NASDAQ:GHDX)
Insider Trades by Quarter for Genomic Health (NASDAQ:GHDX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/19/2017Phillip G. FebboInsiderSell3,174$33.57$106,551.18View SEC Filing  
7/11/2017G Bradley ColeCOOSell5,000$32.53$162,650.00View SEC Filing  
7/5/2017Kimberly J. PopovitsInsiderSell5,000$32.59$162,950.00View SEC Filing  
7/5/2017Kimberly J. PopovitsCEOSell1,468$32.67$47,959.56View SEC Filing  
6/23/2017Steven ShakInsiderSell5,000$33.27$166,350.00View SEC Filing  
6/5/2017Kimberly J. PopovitsInsiderSell5,000$32.32$161,600.00View SEC Filing  
5/23/2017Steven ShakInsiderSell5,000$29.40$147,000.00View SEC Filing  
5/19/2017Fred E CohenDirectorSell8,250$29.54$243,705.00View SEC Filing  
5/18/2017Fred E CohenDirectorSell16,500$29.88$493,020.00View SEC Filing  
5/16/2017Fred E CohenDirectorSell8,250$30.68$253,110.00View SEC Filing  
5/3/2017Kimberly J. PopovitsInsiderSell5,000$31.77$158,850.00View SEC Filing  
4/24/2017Steven ShakInsiderSell5,000$31.46$157,300.00View SEC Filing  
4/3/2017Kimberly J. PopovitsInsiderSell5,000$31.30$156,500.00View SEC Filing  
3/23/2017Steven ShakInsiderSell5,000$31.26$156,300.00View SEC Filing  
3/20/2017Laura LeberInsiderSell3,072$31.88$97,935.36View SEC Filing  
3/6/2017Kimberly J. PopovitsInsiderSell5,000$31.09$155,450.00View SEC Filing  
2/16/2017Phillip G. FebboInsiderSell2,495$30.09$75,074.55View SEC Filing  
1/23/2017Steven ShakInsiderSell5,000$27.28$136,400.00View SEC Filing  
1/10/2017G Bradley ColeCOOSell5,000$29.22$146,100.00View SEC Filing  
12/5/2016Kimberly J PopovitsInsiderSell5,000$30.02$150,100.00View SEC Filing  
11/3/2016Kimberly J PopovitsInsiderSell5,313$28.88$153,439.44View SEC Filing  
10/11/2016Steven ShakInsiderSell5,000$30.39$151,950.00View SEC Filing  
10/10/2016G Bradley ColeCOOSell8,290$30.59$253,591.10View SEC Filing  
10/6/2016James J. VaughnInsiderSell3,000$29.68$89,040.00View SEC Filing  
9/13/2016Steven ShakInsiderSell5,000$26.83$134,150.00View SEC Filing  
8/23/2016Steven ShakInsiderSell5,000$27.24$136,200.00View SEC Filing  
8/15/2016Felix BakerDirectorBuy100,000$27.02$2,702,000.00View SEC Filing  
8/11/2016G Bradley ColeCOOSell5,000$28.87$144,350.00View SEC Filing  
8/8/2016James J. VaughnInsiderSell3,000$28.74$86,220.00View SEC Filing  
7/19/2016Steven ShakInsiderSell5,000$27.42$137,100.00View SEC Filing  
7/6/2016G Bradley ColeCOOSell5,000$26.64$133,200.00View SEC Filing  
6/21/2016Steven ShakInsiderSell5,000$25.77$128,850.00View SEC Filing  
6/9/2016G Bradley ColeCOOSell5,000$26.62$133,100.00View SEC Filing  
6/6/2016James J VaughnInsiderSell1,997$28.00$55,916.00View SEC Filing  
5/16/2016G Bradley ColeCOOSell5,000$27.60$138,000.00View SEC Filing  
5/10/2016Phillip G FebboInsiderSell6,324$27.20$172,012.80View SEC Filing  
5/4/2016Steven ShakInsiderSell10,000$25.43$254,300.00View SEC Filing  
1/13/2016Randall S. LivingstonDirectorSell1,250$32.14$40,175.00View SEC Filing  
1/12/2016G Bradley ColeCOOSell4,000$31.69$126,760.00View SEC Filing  
1/7/2016James J. VaughninsiderSell2,000$33.63$67,260.00View SEC Filing  
12/8/2015G Bradley ColeCOOSell4,000$29.26$117,040.00View SEC Filing  
12/7/2015James J. VaughninsiderSell2,000$29.33$58,660.00View SEC Filing  
11/10/2015G Bradley ColeCOOSell4,000$26.03$104,120.00View SEC Filing  
9/9/2015G Bradley ColeCOOSell9,664$25.35$244,982.40View SEC Filing  
7/7/2015G Bradley ColeCOOSell4,000$27.53$110,120.00View SEC Filing  
6/9/2015G Bradley ColeCOOSell4,000$26.24$104,960.00View SEC Filing  
4/13/2015Kimberly J PopovitsCEOSell3,000$31.28$93,840.00View SEC Filing  
4/7/2015G Bradley ColeCOOSell4,000$30.44$121,760.00View SEC Filing  
2/2/2015Randall S LivingstonDirectorSell1,000$31.93$31,930.00View SEC Filing  
1/12/2015Kimberly J PopovitsCEOSell3,000$33.46$100,380.00View SEC Filing  
12/8/2014G Bradley ColeCOOSell4,336$32.52$141,006.72View SEC Filing  
11/12/2014Kimberly J PopovitsCEOSell4,300$34.82$149,726.00View SEC Filing  
10/13/2014Kimberly J PopovitsCEOSell3,000$30.78$92,340.00View SEC Filing  
10/8/2014G Bradley ColeCOOSell4,000$28.77$115,080.00View SEC Filing  
9/11/2014Kimberly J PopovitsCEOSell3,000$29.82$89,460.00View SEC Filing  
9/8/2014G Bradley ColeCOOSell4,700$30.09$141,423.00View SEC Filing  
8/14/2014Steven ShakEVPSell13,348$27.36$365,201.28View SEC Filing  
8/13/2014Steven ShakEVPSell7,000$27.25$190,750.00View SEC Filing  
7/14/2014Kimberly J PopovitsCEOSell3,000$26.59$79,770.00View SEC Filing  
7/8/2014G Bradley ColeCOOSell2,300$27.05$62,215.00View SEC Filing  
7/1/2014Steven ShakEVPSell7,000$27.00$189,000.00View SEC Filing  
4/14/2014Steven ShakEVPSell7,000$26.25$183,750.00View SEC Filing  
4/8/2014G Bradley ColeCOOSell3,000$27.00$81,000.00View SEC Filing  
3/14/2014Steven ShakEVPSell7,000$28.36$198,520.00View SEC Filing  
2/18/2014Kathy HibbsSVPSell1,312$27.88$36,578.56View SEC Filing  
1/15/2014Steven ShakEVPSell7,000$31.51$220,570.00View SEC Filing  
1/13/2014Kimberly PopovitsCEOSell2,500$30.00$75,000.00View SEC Filing  
12/17/2013Steven ShakCMOSell14,000$29.57$413,980.00View SEC Filing  
12/12/2013Kimberly PopovitsCEOSell2,500$30.68$76,700.00View SEC Filing  
12/9/2013Dean SchornoCFOSell3,000$33.25$99,750.00View SEC Filing  
10/15/2013Steven ShakCMOSell5,000$29.67$148,350.00View SEC Filing  
10/10/2013Kimberly PopovitsCEOSell2,500$30.00$75,000.00View SEC Filing  
10/9/2013G Bradley ColeCOOSell2,500$29.95$74,875.00View SEC Filing  
9/18/2013Steven ShakCMOSell5,000$33.73$168,650.00View SEC Filing  
9/12/2013Kimberly PopovitsCEOSell2,500$34.31$85,775.00View SEC Filing  
9/9/2013G Bradley ColeCOOSell2,500$32.53$81,325.00View SEC Filing  
9/6/2013Dean L SchornoCFOSell4,000$32.90$131,600.00View SEC Filing  
9/3/2013Randall LivingstonDirectorSell1,000$31.49$31,490.00View SEC Filing  
8/14/2013Steven ShakCMOSell5,000$32.98$164,900.00View SEC Filing  
8/12/2013Kimberly PopovitsCEOSell2,500$33.03$82,575.00View SEC Filing  
8/9/2013Dean SchornoCFOSell4,000$33.15$132,600.00View SEC Filing  
8/7/2013G Bradley ColeCOOSell2,500$33.66$84,150.00View SEC Filing  
7/23/2013Steven ShakCMOSell5,000$35.33$176,650.00View SEC Filing  
7/12/2013Kimberly J PopovitsCEOSell5,000$34.61$173,050.00View SEC Filing  
7/9/2013Dean L SchornoCFOSell4,000$33.81$135,240.00View SEC Filing  
7/8/2013G Bradley ColeCOOSell2,500$33.33$83,325.00View SEC Filing  
6/18/2013Steven ShakCMOSell5,000$33.52$167,600.00View SEC Filing  
6/12/2013Kimberly J PopovitsCEOSell5,000$35.68$178,400.00View SEC Filing  
6/10/2013Dean L SchornoCFOSell4,000$35.88$143,520.00View SEC Filing  
6/5/2013Felix BakerDirectorBuy381,432$36.16$13,792,581.12View SEC Filing  
6/5/2013G Bradley ColeCOOSell2,500$36.47$91,175.00View SEC Filing  
6/3/2013Felix BakerDirectorBuy179,583$36.71$6,592,491.93View SEC Filing  
5/29/2013Felix BakerDirectorBuy121,266$36.89$4,473,502.74View SEC Filing  
5/24/2013Felix BakerDirectorBuy79,417$36.93$2,932,869.81View SEC Filing  
5/22/2013Kathy L HibbsSVPSell1,000$37.48$37,480.00View SEC Filing  
5/21/2013Steven ShakCMOSell5,000$37.19$185,950.00View SEC Filing  
5/16/2013Felix BakerDirectorBuy71,439$36.45$2,603,951.55View SEC Filing  
5/15/2013Randall S LivingstonDirectorSell1,337$35.83$47,904.71View SEC Filing  
5/14/2013Felix BakerDirectorBuy240,426$34.34$8,256,228.84View SEC Filing  
5/13/2013Kathy L HibbsSVPSell1,250$34.42$43,025.00View SEC Filing  
5/13/2013Kimberly J PopovitsCEOSell5,000$34.70$173,500.00View SEC Filing  
5/9/2013Dean L SchornoCFOSell4,000$36.02$144,080.00View SEC Filing  
5/8/2013G Bradley ColeCOOSell2,500$35.99$89,975.00View SEC Filing  
2/21/2013Felix BakerDirectorBuy49,085$27.78$1,363,581.30View SEC Filing  
2/14/2013Woodrow A Myers JrDirectorSell41,250$28.40$1,171,500.00View SEC Filing  
2/11/2013Felix BakerDirectorBuy116,360$28.15$3,275,534.00View SEC Filing  
11/26/2012Randall S LivingstonDirectorSell2,000$27.84$55,680.00View SEC Filing  
11/21/2012Felix BakerDirectorBuy229,300$26.83$6,152,119.00View SEC Filing  
11/14/2012Felix BakerDirectorBuy103,167$27.32$2,818,522.44View SEC Filing  
11/13/2012Felix BakerDirectorBuy823,772$27.81$22,909,099.32View SEC Filing  
11/12/2012Dean L SchornoCFOSell3,000$28.00$84,000.00View SEC Filing  
11/8/2012G Bradley ColeCOOSell2,500$28.62$71,550.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Genomic Health (NASDAQ:GHDX)
Latest Headlines for Genomic Health (NASDAQ:GHDX)
Source:
DateHeadline
americanbankingnews.com logoInsider Selling: Genomic Health, Inc. (NASDAQ:GHDX) Insider Sells 3,174 Shares of Stock
www.americanbankingnews.com - July 21 at 7:50 PM
finance.yahoo.com logoGenomic Health to Announce Second Quarter 2017 Financial Results and Host Conference Call on Tuesday, August 1, 2017
finance.yahoo.com - July 20 at 4:49 PM
americanbankingnews.com logoZacks: Brokerages Anticipate Genomic Health, Inc. (GHDX) Will Post Quarterly Sales of $86.09 Million
www.americanbankingnews.com - July 16 at 8:42 AM
americanbankingnews.com logoZacks: Analysts Anticipate Genomic Health, Inc. (GHDX) Will Announce Earnings of -$0.06 Per Share
www.americanbankingnews.com - July 14 at 12:28 PM
americanbankingnews.com logoG Bradley Cole Sells 5,000 Shares of Genomic Health, Inc. (NASDAQ:GHDX) Stock
www.americanbankingnews.com - July 13 at 8:16 PM
finance.yahoo.com logoUpdated St. Gallen International Breast Cancer Guidelines Reinforce Important Role of Genomic Testing in Treatment of Early Breast Cancer
finance.yahoo.com - July 12 at 7:44 PM
americanbankingnews.com logoKimberly J. Popovits Sells 1,468 Shares of Genomic Health, Inc. (NASDAQ:GHDX) Stock
www.americanbankingnews.com - July 7 at 9:02 PM
americanbankingnews.com logoGenomic Health, Inc. (NASDAQ:GHDX) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - July 7 at 10:53 AM
americanbankingnews.com logoKimberly J. Popovits Sells 5,000 Shares of Genomic Health, Inc. (GHDX) Stock
www.americanbankingnews.com - July 6 at 10:23 PM
finance.yahoo.com logoETFs with exposure to Genomic Health, Inc. : June 29, 2017
finance.yahoo.com - June 29 at 10:48 PM
americanbankingnews.com logoInsider Selling: Genomic Health, Inc. (GHDX) Insider Sells 5,000 Shares of Stock
www.americanbankingnews.com - June 27 at 7:51 PM
americanbankingnews.com logoZacks: Brokerages Expect Genomic Health, Inc. (GHDX) Will Announce Quarterly Sales of $86.09 Million
www.americanbankingnews.com - June 22 at 11:36 AM
americanbankingnews.com logoZacks: Brokerages Expect Genomic Health, Inc. (GHDX) Will Announce Earnings of -$0.06 Per Share
www.americanbankingnews.com - June 20 at 10:28 AM
finance.yahoo.com logoGenomic Health, Inc. :GHDX-US: Earnings Analysis: Q1, 2017 By the Numbers : June 14, 2017
finance.yahoo.com - June 14 at 12:04 PM
finance.yahoo.com logoWhy Is Genomic Health (GHDX) Up 7.1% Since the Last Earnings Report?
finance.yahoo.com - June 13 at 11:19 AM
americanbankingnews.com logoGenomic Health, Inc. (GHDX) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - June 12 at 9:58 AM
americanbankingnews.com logoGenomic Health, Inc. (GHDX) Receives Hold Rating from Jefferies Group LLC
www.americanbankingnews.com - June 12 at 8:28 AM
americanbankingnews.com logoGenomic Health, Inc. (GHDX) Insider Sells $161,600.00 in Stock
www.americanbankingnews.com - June 7 at 10:52 PM
finance.yahoo.com logoGenomic Health Presents Data Further Demonstrating Ability of Oncotype DX® Tests to Optimize Outcomes in Patients Across Cancer Types
finance.yahoo.com - June 2 at 6:45 PM
americanbankingnews.com logoBrokers Offer Predictions for Genomic Health, Inc.'s Q2 2017 Earnings (GHDX)
www.americanbankingnews.com - June 2 at 7:08 AM
americanbankingnews.com logoQ3 2017 EPS Estimates for Genomic Health, Inc. (GHDX) Lowered by Analyst
www.americanbankingnews.com - June 1 at 9:44 AM
finance.yahoo.com logoGenomic Health (GHDX) Looks Good: Stock Adds 5.2% in Session
finance.yahoo.com - May 31 at 5:22 PM
fool.com logo3 Things Investors Should Know About Genomic Health Stock
www.fool.com - May 30 at 3:32 PM
finance.yahoo.com logoGenomic Health Announces Presentation of Eight Oncotype DX® Studies at the 2017 American Society of Clinical Oncology Annual Meeting Reinforcing Unique Impact Across Cancer Types
finance.yahoo.com - May 30 at 11:03 AM
americanbankingnews.com logoGenomic Health, Inc. (GHDX) Expected to Post Quarterly Sales of $86.39 Million
www.americanbankingnews.com - May 27 at 9:46 AM
americanbankingnews.com logoGenomic Health, Inc. (GHDX) Insider Steven Shak Sells 5,000 Shares
www.americanbankingnews.com - May 25 at 8:05 PM
finance.yahoo.com logoGenomic Health to Present at Jefferies 2017 Healthcare Conference
finance.yahoo.com - May 25 at 7:46 PM
americanbankingnews.com logoGenomic Health, Inc. (GHDX) Director Sells $243,705.00 in Stock
www.americanbankingnews.com - May 23 at 10:37 PM
americanbankingnews.com logoGenomic Health, Inc. (GHDX) Director Sells $493,020.00 in Stock
www.americanbankingnews.com - May 22 at 7:46 PM
americanbankingnews.com logoGenomic Health, Inc. (GHDX) Director Sells $253,110.00 in Stock
www.americanbankingnews.com - May 18 at 10:23 PM
americanbankingnews.com logoGenomic Health, Inc. (GHDX) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - May 16 at 9:46 AM
fool.com logoGenomic Health, Inc. Waits for Reimbursement
www.fool.com - May 15 at 5:31 PM
finance.yahoo.com logoProspective Oncotype DX® Genomic Prostate Score™ Test Data Presented at AUA and Published in Urology Establish Test's Ability to Increase Use and Persistence on Active Surveillance in Prostate Cancer Patients
finance.yahoo.com - May 13 at 9:48 AM
finance.yahoo.com logoOncotype DX® Genomic Prostate Score™ (GPS) Test Predicts 10-year Risk of Prostate Cancer-specific Death and Metastases in Patients with Early-stage Disease
finance.yahoo.com - May 12 at 6:05 PM
finance.yahoo.com logoGenomic Health, Inc. – Value Analysis (NASDAQ:GHDX) : May 12, 2017
finance.yahoo.com - May 12 at 6:05 PM
americanbankingnews.com logoBrokers Issue Forecasts for Genomic Health, Inc.'s Q2 2017 Earnings (GHDX)
www.americanbankingnews.com - May 12 at 10:20 AM
finance.yahoo.com logoGenomic Health, Inc. breached its 50 day moving average in a Bearish Manner : GHDX-US : May 11, 2017
finance.yahoo.com - May 11 at 6:00 PM
americanbankingnews.com logoGenomic Health, Inc. (GHDX) Posts Quarterly Earnings Results, Misses Estimates By $0.01 EPS
www.americanbankingnews.com - May 11 at 3:25 PM
americanbankingnews.com logoJefferies Group Comments on Genomic Health, Inc.'s Q4 2017 Earnings (GHDX)
www.americanbankingnews.com - May 11 at 12:46 PM
finance.yahoo.com logoEdited Transcript of GHDX earnings conference call or presentation 9-May-17 8:30pm GMT
finance.yahoo.com - May 10 at 10:34 PM
americanbankingnews.com logoJefferies Group LLC Reaffirms Hold Rating for Genomic Health, Inc. (GHDX)
www.americanbankingnews.com - May 10 at 8:21 PM
finance.yahoo.com logoGenomic Health to Present at Bank of America Merrill Lynch 2017 Health Care Conference
finance.yahoo.com - May 10 at 11:14 AM
marketbeat.com logoGenomic Health reports 1Q loss
marketbeat.com - May 9 at 5:44 PM
finance.yahoo.com logoGenomic Health Announces First Quarter 2017 Financial Results and Reports Recent Business Progress
finance.yahoo.com - May 9 at 5:17 PM
finance.yahoo.com logoInvestor Network: Genomic Health, Inc. to Host Earnings Call
finance.yahoo.com - May 9 at 11:40 AM
finance.yahoo.com logoBlog Coverage: Genomic Health Announces Favorable LCD on Medicare Coverage for Use of Oncotype DX Genomic Prostate Score
finance.yahoo.com - May 8 at 8:30 AM
americanbankingnews.com logoGenomic Health, Inc. (GHDX) Insider Sells $158,850.00 in Stock
www.americanbankingnews.com - May 5 at 9:04 AM
streetinsider.com logoRaymond James Downgrades Genomic Health Inc. (GHDX) to Market Perform
www.streetinsider.com - May 4 at 5:34 PM
finance.yahoo.com logoGenomic Health Announces Favorable Draft Local Coverage Determination (LCD) on Medicare Coverage for Use of Oncotype DX® Genomic Prostate Score™ in Patients with Favorable Intermediate-risk Prostate Cancer
finance.yahoo.com - May 4 at 5:34 PM
americanbankingnews.com logo$85.97 Million in Sales Expected for Genomic Health, Inc. (GHDX) This Quarter
www.americanbankingnews.com - May 4 at 3:06 PM

Social

Chart

Genomic Health (GHDX) Chart for Wednesday, July, 26, 2017

This page was last updated on 7/26/2017 by MarketBeat.com Staff